Condition
Normal Tension Glaucoma (NTG)
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownSingle-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel DilationNCT07354477 · 2026-02-20
ACTIVE_NOT_RECRUITINGDSLT in Normal Tension Glaucoma (NTG) Asian EyesNCT07300852 · 2026-01-01
NOT_YET_RECRUITINGOptic Nerve Head Evaluation Through Multimodal Blood Flow Analysis: a Prospective Observational, Multi-center StudyNCT07075887 · 2025-10-01
NOT_YET_RECRUITINGStudy of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)NCT06030193 · 2025-08-13
COMPLETED24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP MonitoringNCT06689696 · 2025-02-19
COMPLETEDTrabecular Microbypass IStent in Patients with GlaucomaNCT06630546 · 2022-05-16
COMPLETEDA Study to Evaluate Safety and Tolerability of QLS-101 in NTGNCT04857827 · 2021-09-15
COMPLETEDCommon interventions
QLS-111 ophthalmic solution (0.015%)DRUG2Direct Selective Laser Trabeculoplasty (DSLT)DEVICE1first generation iStent (Glaukos, San Clemente, CA, USA) insertionDEVICE1miLens systemDEVICE1phacoemulsificationDEVICE1QLS-101DRUG1QLS-111 Ophthalmic Solution (0.075%)DRUG1Timolol maleate PF 0.5% ophthalmic solutionDRUG1Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)DRUG1
Leading sponsors
Trial status mix
COMPLETED4
NOT_YET_RECRUITING2
ACTIVE_NOT_RECRUITING1
Phase mix
PHASE23
NA2
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.